According to GlobalData’s medical device pipeline database, 41 Reversible Contraceptive Devices devices are in various stages of development globally. GlobalData’s report Reversible Contraceptive Devices provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, 23 are in active development, while the remaining 19 are in an inactive stage of development. There are 12 products in the early stages of development, and the remaining 11 are in the late stages of development.
Reproductive health devices are used to prevent pregnancy, diagnose and treat reproductive health conditions, and assist with fertility. They are a broad category of devices that can be used by men and women of all ages. Reversible contraceptive devices are used as birth control to prevent unwanted pregnancy. They are inserted or implanted into women of child-bearing age, often for long periods of time. Reversible Contraceptive Devices includes Intrauterine Devices (IUDs), Diaphragms and Implants.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Reversible Contraceptive Devices pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Reversible Contraceptive Devices devices. Overall, most of these Reversible Contraceptive Devices pipeline devices are being developed by private entities.
Key players involved in the active development of Reversible Contraceptive Devices include Evestra, Agile Therapeutics, Contrel Europe, OCON Medical, Teva Pharmaceuticals USA, Sebela Pharmaceuticals, Merck, Dare Bioscience, Laboratoire HRA Pharma and Lubrizol Life Science Health.
For a complete picture of the developmental pipeline for Reversible Contraceptive Devices devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.